SUBSCRIBE
SUBSCRIBE
News   Drug Development

Phenomix Corporation Announces PHX1149 Phase 2b Clinical Trial Results for Type 2 Diabetes

May 19, 2008 | 
1 min read
SAN DIEGO--(BUSINESS WIRE)--Phenomix Corporation announced today that PHX1149, a dipeptidyl peptidase-4 (DPP-4) inhibitor, demonstrated positive results in a Phase 2b clinical trial for the treatment of Type 2 diabetes.
Clinical research Phase 2
Phenomix Corporation
MORE ON THIS TOPIC
An architect designs a building on a laptop. Art collage.
Insights
Multispecifics are transforming the CDMO development architecture
August 28, 2026
 · 
6 min read
 · 
Jennifer C. Smith-Parker
3D Paper Cut Pair of Lung dotted with yellow tumor bacteria infection spread across on a blue background with no text. Yellow dots as virus infection in the lungs. Vector Illustration.
Drug Development
Generate Bio drops as data accidentally leaked ahead of European conference
August 27, 2026
 · 
2 min read
 · 
Gabrielle Masson
A contemporary artistic collage featuring a hand holding a trophy. The concept of victory and achievement.
Immunology and inflammation
AstraZeneca, Amgen notch another late-stage win for Tezspire, this time in esophagitis
August 27, 2026
 · 
2 min read
 · 
Tristan Manalac
Insights
Fragile X at a turning point: Breaking through the clinical bottleneck
August 27, 2026
 · 
1 min read
 · 
Jennifer C. Smith-Parker